Ruxolitinib (original) (raw)

• Fresh from the Pipeline
• Published: 01 February 2012

Nature Reviews Drug Discovery volume 11, pages 103–104 (2012)Cite this article

• 4550 Accesses
• 206 Citations
• 9 Altmetric
• Metrics details

Subjects

Abstract

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

References

1. Vannucchi, A. M. et al. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J. Clin. 59, 171–191 (2009).
   Article Google Scholar
2. Quintás-Cardama, A. et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Rev. Drug Discov. 10, 127–140 (2011).
   Article Google Scholar
3. Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).
   Article Google Scholar
4. US Food and Drug Administration. FDA labeling information — Jakafi. FDA website [online], (2011).
5. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010).
   Article CAS Google Scholar
6. Silver, R. T. et al. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117, 6669–6672 (2011).
   Article CAS Google Scholar
7. Mesa, R. A. et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) Phase 2 trial E4903. Blood 116, 4436–4438 (2010).
   Article CAS Google Scholar
8. Cervantes, F. et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br. J. Haematol. 129, 771–775 (2005).
   Article CAS Google Scholar
9. Thepot, S. et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116, 3735–3742 (2010).
   Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

1. Ruben A. Mesa is at the Division of Hematology & Medical Oncology, Mayo Clinic, Scottsdale, Arizona 85259, USA.,
   Ruben A. Mesa
2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,
   Uma Yasothan
3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.,
   Peter Kirkpatrick

Authors

1. Ruben A. Mesa
2. Uma Yasothan
3. Peter Kirkpatrick

Corresponding authors

Correspondence toRuben A. Mesa, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Mesa, R., Yasothan, U. & Kirkpatrick, P. Ruxolitinib.Nat Rev Drug Discov 11, 103–104 (2012). https://doi.org/10.1038/nrd3652

Download citation

• Published: 01 February 2012
• Issue date: February 2012
• DOI: https://doi.org/10.1038/nrd3652

This article is cited by